Upstream Bio, Inc. UPB Net unrealized gains (losses) on securities still held
Net unrealized gains (losses) on securities still held at other companies
Other financials
Where this comes from
Reported directly by Upstream Bio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax.
The official record: Upstream Bio, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Upstream Bio, Inc.'s net unrealized gains (losses) on securities still held.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Upstream Bio, Inc.'s net unrealized gains (losses) on securities still held?
- Upstream Bio, Inc. (UPB) reported net unrealized gains (losses) on securities still held of -$430K in Q1 2026.
- How has Upstream Bio, Inc.'s net unrealized gains (losses) on securities still held changed year-over-year?
- Upstream Bio, Inc.'s net unrealized gains (losses) on securities still held decreased by 209.4% year-over-year, from $393K to -$430K.
- What is the long-term trend for Upstream Bio, Inc.'s net unrealized gains (losses) on securities still held?
- Over 2 years (2023 to 2025), Upstream Bio, Inc.'s net unrealized gains (losses) on securities still held has grown at a 414.1% compound annual growth rate (CAGR), from $21K to $555K.
- What does net unrealized gains (losses) on securities still held mean?
- This metric measures the change in the fair value of investment securities held by the company that have not yet been sold. It reflects the unrealized appreciation or depreciation of the company's treasury or investment portfolio based on market price fluctuations. This provides insight into the performance of the company's cash management and investment strategy outside of its core biotechnology research activities.